Zoetis Inc. $ZTS Stake Increased by Dividend Assets Capital LLC

Dividend Assets Capital LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 21.1% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 51,991 shares of the company’s stock after acquiring an additional 9,052 shares during the quarter. Dividend Assets Capital LLC’s holdings in Zoetis were worth $6,146,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Brighton Jones LLC boosted its position in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares during the period. Empowered Funds LLC increased its holdings in shares of Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares during the period. Intech Investment Management LLC lifted its position in shares of Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC lifted its position in shares of Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares in the last quarter. Finally, Glenview Trust co boosted its holdings in shares of Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after purchasing an additional 506 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of ZTS opened at $74.73 on Monday. The firm has a market cap of $31.33 billion, a PE ratio of 12.39, a PEG ratio of 1.17 and a beta of 0.75. The firm’s 50 day moving average price is $84.04 and its 200 day moving average price is $109.31. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a twelve month low of $71.47 and a twelve month high of $161.77.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. Zoetis’s dividend payout ratio is presently 35.16%.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
• Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc (NYSE:ZTS) Dividend Quality Draws Focus
• Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors…
• Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action…

Analyst Ratings Changes

Several research analysts have weighed in on ZTS shares. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Barclays decreased their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Stifel Nicolaus dropped their price target on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research note on Friday, June 26th. TD Cowen dropped their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. Finally, Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $126.92.

Insider Activity

In other news, Director Michael B. Mccallister bought 3,000 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the purchase, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This represents a 13.94% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frank A. Damelio bought 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 11,650 shares of company stock valued at $886,384 over the last 90 days. 0.22% of the stock is currently owned by company insiders.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.